G protein-coupled receptor class C group 5 member AGenealiases: GPCR5A · PEIG-1 · RAI3 · RAIG1 · TIG1
Q-omics provides the consensus-scored GPRC5A profile across patient tissues and cancer cell-line models. GPRC5A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPRC5A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GPRC5A protein abundance shows 26,529 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where GPRC5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPRC5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPRC5A survival associations across molecular data types. GPRC5A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPRC5A RNA expression–survival associations across cancer types. High GPRC5A expression shows unfavorable associations in KIRC, KIRP, PAAD, LGG and LUSC, but favorable associations in ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPRC5A RNA expression.
This table summarizes GPRC5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPRC5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPRC5A shows lower tumor expression in KIRC, KICH, LUAD and LUSC and higher tumor expression in STAD and BRCA. The KIRC box plot shows higher GPRC5A RNA expression in normal versus tumor tissue (log2 FC = −2.490, t-test p < 0.001).
This table shows molecular features associated with GPRC5A in patient tissues and cancer cell lines. In patient samples, GPRC5A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPRC5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
